Wuhan Humanwell Acquires US Generic Drugmaker for $550 Million

Wuhan Humanwell Healthcare will acquire Epic Pharma, a New York state generic drug manufacturer, for $550 million. In a brief announcement, Humanwell said it would invest $270 million to create a US subsidiary, which would then own Epic. Formed in 2008, Epic bought a generic drug manufacturing previously owned by Sandoz. It produces a number of generic drugs and provides contract manufacturing services. In 2015, Epic said its revenues exceeded $120 million per year. More details.... Stock Symbol: (SHA: 600079) Share this with colleagues: // //